Background: Acute myeloid leukaemia is considered one of the heterogeneous hematologic cancers that have a range of therapeutic modalities, genetic abnormalities, and prognoses. AML treatment that is effective is still difficult. Increasing anti-tumor response by inhibiting immunological checkpoints is an appealing approach for leukaemia treatments. An essential immunological checkpoint known as CD200 is the ligand for CD200 receptor (CD200R), which is present on myeloid and lymphoid cells. CD200R limits anti-tumor immune responses. Aim of work: To research the relationship between CD200 and the response outcome to induction therapy in adult AML Egyptian patients. Methods: Ain Shams University's clinical pathology department, internal medicine department, clinical hematology and bone marrow transplantation center, and flow cytometry laboratory all participated in this prospective cross-sectional study on 68 adult patients who were recently diagnosed with acute myeloid leukaemia. Results: Median of CD200 expression was 7.8 (1.3–45) for the responder group compared to 87.7 (77–88.6) for the non-responder group, Compared to the responder group, the CD200 % in the non-responder group had a statistically significant greater value (p 0.001). According to the CD200 level, there was a statistically significant difference between the responder group and the non-responder group with a p-value of (p0.001). The higher positive CD200 was found in non-responder group 31 patients (100%) compared to responder group 18 patients (48.6%). Conclusion: AML development may be influenced by CD200 expression in myeloid blasts from patients with the disease. In the future, this marker's analysis may be used as a prognostic indicator and to direct treatment for AML patients.